BioCentury
ARTICLE | Company News

FDA approves GSK's triple combo for COPD maintenance

September 19, 2017 10:09 PM UTC

FDA approved an NDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol for maintenance treatment of chronic obstructive pulmonary disease. GSK said Trelegy Ellipta is the first once-daily single inhaler triple therapy approved for COPD in the U.S.

Trelegy Ellipta is specifically indicated for COPD patients already receiving fixed-dose Breo Ellipta fluticasone furoate/vilanterol with or without Incruse Ellipta umeclidinium. ...